PET imaging of PD-L1 with a small molecule radiotracer.
作者信息
Zhao Yajie, Hsu Jessica C, Hu Shuo, Cai Weibo
机构信息
Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, China.
National Clinical Research Center for Geriatric Disorders (Xiangya), Changsha, China.
出版信息
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1578-1581. doi: 10.1007/s00259-024-06663-4.
Abstract
摘要
相似文献
1
PET imaging of PD-L1 with a small molecule radiotracer.
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1578-1581. doi: 10.1007/s00259-024-06663-4.
2
In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Mol Imaging Biol. 2021 Apr;23(2):241-249. doi: 10.1007/s11307-020-01544-2. Epub 2020 Oct 23.
3
Site-Specific Immuno-PET Tracer to Image PD-L1.
Mol Pharm. 2019 May 6;16(5):2028-2036. doi: 10.1021/acs.molpharmaceut.9b00010. Epub 2019 Mar 25.
4
Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
J Nucl Med. 2017 Apr;58(4):538-546. doi: 10.2967/jnumed.116.177659. Epub 2016 Dec 15.
5
Development and evaluation of biphenyl-based small-molecule radiotracers for PET imaging of PD-L1 in tumor.
Bioorg Med Chem Lett. 2025 Jul 1;122:130187. doi: 10.1016/j.bmcl.2025.130187. Epub 2025 Mar 12.
6
Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer F-BMS-986192.
J Nucl Med. 2020 Dec;61(12):1839-1844. doi: 10.2967/jnumed.119.241364. Epub 2020 May 1.
7
Synthesis and Biologic Evaluation of a Novel F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression.
J Nucl Med. 2018 Mar;59(3):529-535. doi: 10.2967/jnumed.117.199596. Epub 2017 Oct 12.
8
[F]AlF-NOTA-PCP2: a novel PET/CT tracer for enhanced PD-L1 heterogeneity imaging and comparative analysis with [F]AlF-NOTA-WL12 in glioblastoma xenografts.
Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3161-3175. doi: 10.1007/s00259-024-06743-5. Epub 2024 May 7.
9
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
Nat Commun. 2018 Nov 7;9(1):4664. doi: 10.1038/s41467-018-07131-y.
10
A Novel Small Cyclic Peptide-Based Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors.
Mol Pharm. 2022 Jan 3;19(1):138-147. doi: 10.1021/acs.molpharmaceut.1c00694. Epub 2021 Dec 15.
引用本文的文献
1
68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study.
Clin Cancer Res. 2025 Jul 15;31(14):2989-3001. doi: 10.1158/1078-0432.CCR-25-0160.
2
Preclinical and first‑in‑human evaluation of [Ga]Ga-DOTA-PEG-Asp-PDL1P PET imaging to assess tumor PD-L1 expression.
Eur J Nucl Med Mol Imaging. 2025 Mar 3. doi: 10.1007/s00259-025-07173-7.
3
Noninvasive Monitoring of Programmed Death-Ligand 2 Expression with Positron Emission Tomography using Ga-labeled Peptide Antagonist in Preclinical and Exploratory Human Studies.
Research (Wash D C). 2024 Nov 1;7:0523. doi: 10.34133/research.0523. eCollection 2024.
本文引用的文献
1
Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics.
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1582-1592. doi: 10.1007/s00259-024-06610-3. Epub 2024 Jan 22.
2
Development, Characterization, and Radiation Dosimetry Studies of F-BMS-986229, a F-Labeled PD-L1 Macrocyclic Peptide PET Tracer.
Mol Imaging Biol. 2024 Apr;26(2):301-309. doi: 10.1007/s11307-023-01889-4. Epub 2023 Dec 20.
3
The discovery and evaluation of [F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement.
Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):978-990. doi: 10.1007/s00259-023-06527-3. Epub 2023 Dec 5.
4
[Ga]Ga-AUNP-12 PET imaging to assess the PD-L1 status in preclinical and first-in-human study.
Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):369-379. doi: 10.1007/s00259-023-06447-2. Epub 2023 Sep 28.
5
Translational molecular imaging and drug development in Parkinson's disease.
Mol Neurodegener. 2023 Feb 10;18(1):11. doi: 10.1186/s13024-023-00600-z.
6
CD8 T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy.
Cell Rep Med. 2023 Jan 17;4(1):100878. doi: 10.1016/j.xcrm.2022.100878. Epub 2023 Jan 3.
7
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Lancet. 2022 Oct 1;400(10358):1103-1116. doi: 10.1016/S0140-6736(22)01658-0. Epub 2022 Sep 10.
8
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades.
Front Immunol. 2022 Aug 3;13:920021. doi: 10.3389/fimmu.2022.920021. eCollection 2022.
9
Preclinical and first-in-human evaluation of F-labeled D-peptide antagonist for PD-L1 status imaging with PET.
Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4312-4324. doi: 10.1007/s00259-022-05876-9. Epub 2022 Jul 14.
10
Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [Ga]Ga-NOTA-Nb109.
Quant Imaging Med Surg. 2022 Jun;12(6):3300-3313. doi: 10.21037/qims-21-991.
Zotero 插件